Heather Johnson
Contributing Writer
- All
- Deals
- Devices and Diagnostics
- Digital
- Genetics
- Pharma
Emerging Glaucoma Devices See Beyond IOP
The glaucoma space has been dominated by a host of products designed to lower intraocular pressure (IOP) – minimally invasive glaucoma surgery (MIGS) devices and ...
Read More 
9 Steps to Launching a Product
Editor's Note: The FDA just approved Allergan's Durysta (bimatoprost implant) 10 mcg for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension on ...
Read More 
Glaucoma 360: Promising data as the industry considers value
“Innovation remains the largest driver of healthcare cost increase,” said David Parke II, MD, American Academy of Ophthalmology CEO, during the Glaucoma Research Foundation’s (GRF) ...
Read More 
Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?
SAN FRANCISCO – Nemus Bioscience, a biopharmaceutical company based in Southern California, came to the Glaucoma 360 New Horizons Forum here in February to make ...
Read More 
How Glaucoma Device Companies Raise Funding to Navigate ‘Death Valley’
SAN FRANCISCO – At the Glaucoma 360 New Horizons Forum here, Emmett Cunningham, Jr., MD, PhD, moderating a panel on financing for emerging glaucoma device ...
Read More 
Parsing the Challenges of Reimbursement in the Glaucoma Space: Drug and Device Developers Address Elephant in the Room
SAN FRANCISCO – When it comes to securing reimbursement models, ophthalmic device and drug developers are facing mounting pressure. Payers are demanding more evidence on ...
Read More 
The State of the Art of Glaucoma Genetics
SAN FRANCISCO – Advances in glaucoma genetics potentially hold the key to new therapies for prevention, early detection, and a cure, researcher Janey L. Wiggs, ...
Read More